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Polyacrylamide hydrogel (PAAG) has been used as an injectable,
permanent ﬁller for soft-tissue augmentation for more than two
decades. Several complications have been reported worldwide. In
this case report, we present a woman with long-term complica-
tions 15 years after bilateral breast augmentation with PAAG
injections.
© 2015 The Authors. Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fillers for the augmentation and correction of soft-tissue contours are increasing in popularity, and
numerous biomaterials have been developed. The ﬁllers can be grouped as biodegradable, nonbio-
degradable (permanent), and combinations thereof.1
Polyacrylamide hydrogel (PAAG) is a permanent ﬁller that may be used to correct soft-tissue con-
tours in the face or in breast augmentation.2 PAAG is a jellylike, transparent substance containing
approximately 2.5% cross-linked polyacrylamide and 97.5% water. Since the discovery of PAAG, it has
been widely used for industrial purposes and in ophthalmologic procedures. It was ﬁrst used forSurgery, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C,
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tation.3 In 2001, it attained European community certiﬁcation, and since then it has been in clinical use.
PAAG is considered to be a safe tissue ﬁller.4,5 However, an increasing number of complications after
PAAG injection have been reported.6,8 In this case report, we present a 47-year-old woman who
experienced complications 15 years after bilateral breast augmentation with PAAG injections.
Case report
A 44-year-old, Ukrainian woman presented with a tender and painful left breast, exhibiting
asymmetry and palpable masses in March 2009 (Figure 1). In 1994, she underwent a bilateral breast
augmentation with the permanent ﬁller PAAG. According to the patient, the breasts lost their volume
slightly over the years. In August 2008, a subcutaneous nodule measuring 5  5 cm emerged in the
medial lower quadrant of her left breast. After a mammography showed that the nodule was benign,
the nodule was excised. Six months later, the area of excision was ﬁlled with a liquid substance, which
was again removed surgically. Culture of the removed material showed no bacterial contamination. A
few weeks later, a ﬁstula formed at the area of excision, and the patient was treated with antibiotics
without any effect. In March 2009, the patient was referred to the Department of Plastic Surgery,
Aarhus University Hospital.
A blood sample fromMarch 2009 showed increased levels of CRP (C-reactive protein) (1889 nmol/l),
sedimentation reaction (49 mm), and leukocytes (11.6  109/L). Magnetic resonance imaging (MRI)
scan showed a large amount of ﬂuid in the pectoral muscle and in the retro-pectoral space, mostly on
the right side (Figure 3). Another MRI scan, 8 months later, showed decreased collection of ﬂuid on the
right side but increased collection of ﬂuid on the left side, thus indicating further migration of the ﬁller
(Figure 4).
Two years later, in September 2011, the left breast was still painful and twice its original size. In April
2012, the patient underwent surgery. An incisionwasmade in the inframammary sulcus on the left side,
and through subpectoral dissection 930 cc of yellow, clear liquid containingwhite noduleswas removed
from the encapsulated cavity. Postoperatively, the patient received 400 mg of moxiﬂoxacin orally daily
for 7 days as recommended by the distributor (Contura, Copenhagen, Denmark). The drains were
removed 36 h after the operation, and shewas discharged the ﬁrst postoperative day (Figure 2). Neither
a regular culture nor PCR analysis of the samples removed during surgery revealed any pathogens.
Two months postoperatively, the left breast was asymptomatic and natural looking. The right
breast, however, was enlarged and tender. The patient is still being followed up in the outpatient clinic
with regular clinical and radiological examinations.Figure 1. Swelling of the left breast before operation (September 2011).
Figure 2. The day after surgical drainage of PAAG from the left breast (April 2012).
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In a study by Unukovych et al, 106 patients with PAAG breast augmentation were examined.7 They
found that the most frequently reported complications are pain, subcutaneous nodules, breast de-
formities due to swelling, migration, and ﬁstula formation. The patient in this case report experienced
all the above mentioned complications.
This case report conﬁrms that PAAG may be a potentially dangerous ﬁller for breast augmentation,
causing substantial irreversible damage to the breast in previously healthy women.6,10 DifferentFigure 3. Large amount of ﬂuid mostly on the right side (March 2009).
Figure 4. Migration of the ﬂuid to the left breast (November 2009).
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may reduce the foreign body reaction and eventually make it disappear.8 According to Cheng NX et al,
antibiotics have no effect, because microorganisms are very seldom isolated from the tissue samples6
as in this case. Complete gel evacuation using aspiration is very difﬁcult, as the PAAG is scattered
diffusely into the breast tissue and pectoralis muscle. Even after several suction procedures, residual gel
may remain in the breast tissue.9
The only effective treatment of complications is to remove the PAAG surgically. Evacuation of the
main part of the gel is possible by incision and drainage. In order to remove all the PAAG and the
damaged tissue, a subcutaneous mastectomy may be necessary as a last option.3,7
With the increasing interest and availability of ﬁllers for cosmetic use, it is to be expected that
complications of ﬁllers in general will occur more frequently. Therefore, it is important to gather all
possible information about these serious complications and their possible treatment.
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